Structure Therapeutics (GPCR) Change in Account Payables (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Change in Account Payables of -$5.0 million for Q1 2026, down 824.05% year-over-year from $686000.0 in Q1 2025, and up 0.8% quarter-over-quarter from -$5.0 million in Q4 2025.
Powered by 
Analysis
Structure Therapeutics (GPCR) Change in Account Payables (2022 - 2026) Analysis & Trends
Structure Therapeutics' Change in Account Payables history runs 5 years deep, the most recent figure standing at -$5.0 million for Q1 2026.
- In Q1 2026, Change in Account Payables fell 824.05% year-over-year to -$5.0 million; the TTM figure through Mar 2026 stood at -$888000.0 (down 140.85% YoY), while the FY2025 annual figure was $4.8 million, up 44.09% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$5.0 million, up from -$5.0 million in the prior quarter.
- The five-year high for Change in Account Payables was $8.8 million in Q3 2025, with the low at -$5.0 million in Q4 2025.
- The 5-year median for Change in Account Payables is $280000.0 (2025), against an average of $258705.9.
- The sharpest annual moves came in 2023 and 2025: Change in Account Payables soared 1227.42% in 2023, then sank 1083.69% in 2025.
- Structure Therapeutics' Change in Account Payables stood at -$124000.0 in 2022, then jumped by 1227.42% to $1.4 million in 2023, then plunged by 130.26% to -$423000.0 in 2024, then tumbled by 1083.69% to -$5.0 million in 2025, then gained by 0.8% to -$5.0 million in 2026.
- Business Quant data shows GPCR's Change in Account Payables at -$5.0 million in Q1 2026, -$5.0 million in Q4 2025, and $8.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Structure Therapeutics | 10.32 Bn | 10.32 Bn | - | 3.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.31 Mn |
| Mar 31, 2026 | -4.97 Mn |
| Dec 31, 2025 | -5.01 Mn |
| Sep 30, 2025 | 8.81 Mn |
| Jun 30, 2025 | 280,000.00 |
| Mar 31, 2025 | 686,000.00 |
| Dec 31, 2024 | -423,000.00 |
| Sep 30, 2024 | 6.30 Mn |
| Jun 30, 2024 | -4.39 Mn |
| Mar 31, 2024 | 1.82 Mn |
| Dec 31, 2023 | 1.40 Mn |
| Sep 30, 2023 | -2.38 Mn |
| Jun 30, 2023 | 1.05 Mn |
| Mar 31, 2023 | -923,000.00 |
| Dec 31, 2022 | -124,000.00 |
| Sep 30, 2022 | 2.27 Mn |
| Jun 30, 2022 | 1.58 Mn |
| Mar 31, 2022 | -1.56 Mn |